Takeda opens cell therapy manufacturing facility — tucked right in its Boston R&D hub

When Takeda unveiled its translational cell therapy engine early last year, the Japanese pharma made it clear the crew, under Novartis vet Stefan Wildt, is going all the way: clinical expertise, bioengineering chops, world-class collaborations, plus chemistry, manufacturing and control.

The final piece of the puzzle has now fallen in place, with the opening of a 24,000 square-foot cell therapy manufacturing facility at its R&D headquarters in Boston.